Providing advice about the status of all newly licensed medicines



www.scottishmedicines.org.uk

Delta House (8th floor) 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Angela Timoney FRPharmS

Product Update

calcium carbonate equivalent to 500mg calcium, cholecalciferol (vitamin D₃) 800 IU (20 microgram) tablets (Kalcipos-D 500mg/800 IU chewable tablets®) (No: 718/11)

Meda Pharmaceuticals Ltd

08 July 2011

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

calcium carbonate and cholecalciferol (Kalcipos-D®) is accepted for use within NHS Scotland.

Indications under review:

- Prevention and treatment of calcium and vitamin D deficiency in the elderly.
- Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.

This is a new combination product with a different ratio of calcium to cholecalciferol than alternative combination preparations. It is a similar price to an alternative product containing 800IU of cholecalciferol per tablet but is more expensive than some other calcium and cholecalciferol combinations. Any overall budget impact is likely to be small.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 18 May 2011.

Chairman, Scottish Medicines Consortium